73 Results for "

engager

" in MedChemExpress (MCE) Product Catalog:
Products (73)

73 Results for "engager" in MCE Product Catalog:

22
EHT 1864
EHT 1864
0 Images
22 Publications Verification
Art. -Nr.: HY-16659
CAS. Nr.: 754240-09-0
Target:  

Ras

Forschungsgebiete:  

Neurological Disease Cancer

EHT 1864 is an inhibitor of Rac family small GTPases. EHT 1864 directly binds and impairs the ability of this small GTPase to engage critical downstream effectors required for growth transformation. The Kd values are 40, 50, 60, and 230 nM for Rac1, Rac1b, Rac2 and Rac3, respectively. EHT 1864 also potently inhibits other Rac-dependent transformation processes, Tiam1- and Ras-mediated growth transformation. EHT 1864 prevents Aβ 40 and Aβ 42 production in vivo. EHT 1864 dependently suppresses the release of migrasomes from podocytes induced by LPS, PAN, or HG .
3
TRV-120027
TRV-120027
0 Images
3 Cited Publications
Art. -Nr.: HY-P2141
CAS. Nr.: 1234510-46-3
Synonyms: TRV027
Target:  

Angiotensin Receptor Arrestin

Forschungsgebiete:  

Cardiovascular Disease

TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages β-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R-β-arrestin-1-TRPC3-PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II-mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .
3
TRV-120027 TFA
TRV-120027 TFA
0 Images
3 Cited Publications
Art. -Nr.: HY-P2141A
Target:  

Angiotensin Receptor Arrestin

Forschungsgebiete:  

Cardiovascular Disease

TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ?-arrestins while blocking G-protein signaling . TRV120027?TFA induces?acute?catecholamine?secretion?through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the?acute decompensated heart failure (ADHF) treatment .
2
Tarlatamab
Tarlatamab
0 Images
2 Cited Publications
Art. -Nr.: HY-P99575
CAS. Nr.: 2307488-83-9
Synonyms: AMG-757

Target:  

Notch

Forschungsgebiete:  

Inflammation/Immunology Cancer

Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
2
TH588
TH588
0 Images
2 Cited Publications
Art. -Nr.: HY-12814
CAS. Nr.: 1609960-31-7
Reinheit:  99.20%
Target:  

DNA/RNA Synthesis

Forschungsgebiete:  

Cancer

TH588 is first-in-class nudix hydrolase family inhibitor that potently and selectively engage and inhibit the MTH1 (IC50= 5 nM).
1
Mosunetuzumab
Mosunetuzumab
0 Images
1 Cited Publications
Art. -Nr.: HY-P99033
CAS. Nr.: 1905409-39-3
Synonyms: BTCT-4465A; RG-7828; RO7030816

Target:  

CD20 CD3

Forschungsgebiete:  

Inflammation/Immunology Cancer

Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .
1
Pasotuxizumab
Pasotuxizumab
0 Images
1 Cited Publications
Art. -Nr.: HY-P99802
CAS. Nr.: 1442657-12-6
Synonyms: BAY 2010112; AMG 212; MT112

Target:  

CD3

Forschungsgebiete:  

Cancer

Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
1
Gresonitamab
Gresonitamab
0 Images
1 Cited Publications
Art. -Nr.: HY-P99350
CAS. Nr.: 2413817-97-5
Synonyms: AMG 910; Anti-Human CD3xClaudin18 2

Target:  

CD3

Forschungsgebiete:  

Cancer

Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .
1
BRD7586
BRD7586
0 Images
1 Cited Publications
Art. -Nr.: HY-148730
CAS. Nr.: 895460-70-5
Reinheit:  99.03%
Target:  

Bacterial

Forschungsgebiete:  

Cancer

BRD7586 is a potent and selective Streptococcus pyogenes Cas9 (SpCas9) inhibitor. BRD7586 specifically engages SpCas9 but not Cas12a in cells and enhances SpCas9 specificity at multiple loci. BRD7586 inhibits SpCas9 at multiple genomic loci irrespective of the mode of SpCas9 delivery .
1
Pavurutamab
Pavurutamab
0 Images
1 Cited Publications
Art. -Nr.: HY-P99814
CAS. Nr.: 2250292-39-6
Synonyms: AMG-701

Target:  

CD3

Forschungsgebiete:  

Inflammation/Immunology Cancer

Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .
1
Ru(dpp)3(PF6)2
Ru(dpp)3(PF6)2
0 Images
1 Cited Publications
Art. -Nr.: HY-W127832
CAS. Nr.: 123148-15-2
Ru(dpp)3(PF6)2 is a ruthenium (II) polypyridine complex and oxygen-sensing luminophore with excellent photostability and bright orange emission properties based on metal-to-ligand charge transfer (MLCT). Ru(dpp)3(PF6)2 undergoes oxygen-induced collisional luminescence quenching following the Stern-Volmer relationship, and can also engage in Förster-type resonance energy transfer with closed-form BTF6. Featuring excellent photophysical and electrochemical properties, Ru(dpp)3(PF6)2 is applied in studies on quenching-type oxygen sensors based on fluorinated ORMOSIL/xerogels and solid-state light-emitting devices .
Pasritamig
Pasritamig
0 Images
Art. -Nr.: HY-P991015
CAS. Nr.: 2921676-04-0
Synonyms: JNJ-78278343; KLCB-245

Target:  

CD3

Forschungsgebiete:  

Cancer

Pasritamig (JNJ-78278343; KLCB-245) is a bispecific T-cell engager (BiTE) that targets the complex of human kallikrein KLK2 and CD3 receptor. Pasritamig redirects the cytotoxicity of T cells to KLK2-expressing tumor cells and induces T cell-mediated lysis of KLK2-expressing prostate cancer cells. Administered via subcutaneous injection, subcutaneous infusion or intravenous infusion, Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig has a safety profile with an extremely low incidence of cytokine release syndrome and can be safely administered in an outpatient setting. Pasritamig is applicable to the research of metastatic castration-resistant prostate cancer .
Xaluritamig
Xaluritamig
0 Images
Art. -Nr.: HY-P990688
CAS. Nr.: 2559056-68-5
Synonyms: AMG-509

Target:  

CD3

Forschungsgebiete:  

Cancer

Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8 + T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma .
EN1033
EN1033
0 Images
Art. -Nr.: HY-175759
CAS. Nr.: 2193367-28-9
Target:  

Molecular Glues IFNAR

Forschungsgebiete:  

Inflammation/Immunology

EN1033 is a covalent immune regulatory transcription factor 5/8 (IRF5/8) molecular glue degrader. EN1033 degrades IRF5 in a proteasome-dependent manner. EN1033 engages and degrades IRF8 more robustly and rapidly. EN1033 covalently targets C28 and C223 to destabilize and degrade IRF5 and IRF8 respectively, thereby inhibiting their pro-inflammatory transcriptional activity. EN1033 serves as a promising tool for the study of autoimmune and inflammatory disorders .
Obrixtamig
Obrixtamig
0 Images
Art. -Nr.: HY-P990932
CAS. Nr.: 2851943-09-2
Synonyms: BI 764532; OBT 620

Target:  

CD3

Forschungsgebiete:  

Cancer

Obrixtamig (BI 764532; OBT 620) is an CD3E/DLL3-targeting L-κ-G1-h-CH2-CH3_L-λ-G1-h-CH2-CH3 type human antibody. Obrixtamig is a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager. Obrixtamig can be used for research of DLL3-positive small cell lung cancer .
Etevritamab
Etevritamab
0 Images
Art. -Nr.: HY-P99948
CAS. Nr.: 2329692-74-0
Synonyms: AMG-596

Target:  

EGFR CD3

Forschungsgebiete:  

Neurological Disease Cancer

Etevritamab (AMG-596) is a bispecific T-cell engager that targets EGFRvIII and CD3. Etevritamab simultaneously binds CD3 on T cells and EGFRvIII on glioblastoma multiforme cells, thereby forming a bridge structure. Etevritamab triggers T-cell activation, proliferation, secretion of cytotoxic substances, and tumor cell lysis. Etevritamab extends overall survival and induces tumor regression in mouse models of glioblastoma multiforme. Etevritamab can be used for research related to glioblastoma .
Alnuctamab
Alnuctamab
0 Images
Art. -Nr.: HY-P99430
CAS. Nr.: 2296827-07-9
Synonyms: EM901; CC-93269

Target:  

CD3

Forschungsgebiete:  

Inflammation/Immunology Cancer

Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Cizutamig
Cizutamig
0 Images
Art. -Nr.: HY-P990980
CAS. Nr.: 2919209-65-5
Synonyms: CND-106; EMB-06

Target:  

CD3

Forschungsgebiete:  

Inflammation/Immunology Cancer

Cizutamig (CND-106) is a bispecific T-cell engager targeting BCMA and CD3. Cizutamig exhibits immunostimulatory and anti-tumor activities. Cizutamig can be used in research related to relapsed or refractory multiple myeloma and systemic lupus erythematosus .
Alveltamig
Alveltamig
0 Images
Art. -Nr.: HY-P991731
Synonyms: ZG006

Target:  

CD3 Notch

Forschungsgebiete:  

Neurological Disease Cancer

Alveltamig (ZG006) is a trispecific T cell engager targeting Delta-like ligand 3 (DLL3)/CD3, mediating T cell-specific killing of DLL3-expressing tumor cells. Alveltamig can be used for the researches of small cell lung cancer and neuroendocrine carcinoma .
Pacanalotamab
Pacanalotamab
0 Images
Art. -Nr.: HY-P99798
CAS. Nr.: 2251756-52-0
Synonyms: AMG 420; BI-836909

Target:  

CD3

Forschungsgebiete:  

Cancer

Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3E. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .
Assay Types